Published in Tumori on June 08, 2012
Episensitization: Defying Time's Arrow. Front Oncol (2015) 1.04
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol (2011) 3.99
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol (2013) 2.84
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol (2007) 1.75
Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg (2007) 1.63
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer (2004) 1.48
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol (2004) 1.48
Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest (2016) 1.47
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.46
Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther (2003) 1.33
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol (2006) 1.28
Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg (2005) 1.25
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int (2011) 1.24
Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol (2008) 1.19
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology (2008) 1.17
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol (2005) 1.14
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol (2011) 1.14
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther (2011) 1.09
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev (2003) 1.08
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res (2014) 1.08
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol (2012) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev (2010) 1.05
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer (2006) 1.04
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol (2014) 1.00
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer (2013) 0.97
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res (2011) 0.96
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). Int J Radiat Oncol Biol Phys (2005) 0.90
Colon cancer. Crit Rev Oncol Hematol (2004) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori (2005) 0.89
Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci (2013) 0.88
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther (2012) 0.88
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev (2013) 0.87
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf (2014) 0.87
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets (2015) 0.87
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol (2015) 0.87
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. Oncologist (2014) 0.86
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer (2007) 0.85
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.85
Rectal cancer. Crit Rev Oncol Hematol (2008) 0.84
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology (2008) 0.84
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer (2014) 0.83
ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol (2013) 0.82
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol (2014) 0.82
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.82
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol (2013) 0.82
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori (2009) 0.82
Abiraterone acetate in castration-resistant prostate cancer. Anticancer Drugs (2012) 0.82
Neuroendocrine tumors of the larynx: a clinical report and literature review. Tumori (2006) 0.82
Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2012) 0.82
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.82
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int (2014) 0.82
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. Support Cancer Ther (2006) 0.81
Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Rev Proteomics (2014) 0.81
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol (2015) 0.81
Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg (2004) 0.81
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer (2002) 0.80
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. Oncology (2010) 0.80
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol (2012) 0.80
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 0.80
Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. Ther Adv Urol (2012) 0.80
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther (2012) 0.79
Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: a case report. Tumori (2011) 0.79
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Target Oncol (2011) 0.79
Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther (2012) 0.79
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report. Clin Genitourin Cancer (2012) 0.79
Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori (2007) 0.79
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Prostate (2007) 0.79
Everolimus in advanced solid tumors: when to start, early or late? Tumori (2014) 0.79
Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol (2013) 0.78
Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets. Oncoimmunology (2013) 0.78